Dear Customer,

Mallinckrodt Specialty Generics continues to closely monitor developments associated with the coronavirus (COVID-19) pandemic. Our top priority is the health and safety of our employees, customers, and communities, as well as the patients who – now more than ever – are in need of the critical products manufactured at our facilities.

I am writing to share with you that we are still in full production. Numerous measures are being taken across our entire operation to safeguard the health of our employees, our manufacturing environments, and to prevent supply shortages or delivery disruptions related to COVID-19 as the situation progresses.

Health
Based on guidance from the Centers for Disease Control and Prevention (CDC) and other federal and state agencies, our COVID-19 Response Team has taken swift and aggressive measures to protect the health of our staff and limit opportunities for exposure and cross contamination at our facilities. These include:

- Operational containment plans, including restricted access to all manufacturing areas.
- Increased cleaning and sanitization at all facilities.
- Social distancing practices as recommended by the CDC.
- Remote work policy for non-essential employees.
- Cancellation of non-essential travel.
- Restricted visitor access.
- Use of digital/virtual tools in lieu of in-person engagement. We are asking our customers to conduct meetings via phone or video conference.
- Self-reporting and quarantine procedures for employees who experience symptoms or test positive for COVID-19.

Supply
Mallinckrodt Specialty Generics’ ability to manufacture and deliver products to our customers is not affected by the supply chain issues reported in China, India or other impacted countries. With a vertically integrated supply chain, our US based manufacturing sites produce 99% of the active pharmaceutical ingredients (APIs) used in the manufacture of our generic products. 100% of our API manufacturing is conducted at our US plant locations.

Further, we continue to evaluate our robust raw material supply chain and believe we have sufficient inventory and suppliers to support requirements at this time.

To avert any potential workforce disruptions caused by COVID-19, each of our sites have established workforce contingency plans which will enable continuity of operations and limit interruptions to the manufacture and distribution of products.

We will continue to closely monitor the COVID-19 situation and provide updates to you in the weeks ahead. Thank you for your continued partnership as we remain committed to overcome present challenges to meet your needs and those of the patients we serve. Should you have any questions, please reach out to your sales representative.

Best regards,

Spiro Gavaris
President, Mallinckrodt Specialty Generics